These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 39327019

  • 1. Association of Free-to-Total PSA Ratio and 18F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
    Bernardino RM, Lajkosz K, Yin LB, Sayyid RK, Wettstein M, Randhawa H, Cockburn JG, Ahmed S, Thomassian R, Diamandis E, Metser U, Berlin A, Fleshner NE.
    J Nucl Med; 2024 Nov 01; 65(11):1731-1739. PubMed ID: 39327019
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, Tyldesley S, Wilson D, Bénard F.
    Cancer Imaging; 2024 Aug 30; 24(1):117. PubMed ID: 39210431
    [Abstract] [Full Text] [Related]

  • 3. 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy.
    Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, Lin F, Adler S, Eclarinal P, McKinney YL, Citrin D, Dahut W, Wood BJ, Krishnasamy V, Chang R, Levy E, Merino M, Pinto P, Eary JF, Choyke PL.
    J Nucl Med; 2020 Jun 30; 61(6):881-889. PubMed ID: 31676732
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes.
    Ng M, Guerrieri M, Wong LM, Taubman K, Sutherland T, Benson A, Byrne G, Koschel S, Yap K, Starmans M, Ong G, Macleod C, Foo M, Chao M.
    J Nucl Med; 2022 Sep 30; 63(9):1343-1348. PubMed ID: 35058320
    [Abstract] [Full Text] [Related]

  • 6. Predicting 18F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical Recurrence.
    Lee KH, Mena E, Shih J, Lindenberg L, Wood BJ, Pinto PA, Patel KR, Citrin DE, Choyke PL, Turkbey B.
    Acad Radiol; 2024 Apr 30; 31(4):1419-1428. PubMed ID: 37775447
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial.
    Koschel S, Taubman K, Sutherland T, Yap K, Chao M, Guerrieri M, Benson A, Starmans M, Byrne G, Ong G, Macleod C, Foo M, Wong LM, Gyomber D, Ng M.
    Eur J Nucl Med Mol Imaging; 2021 Oct 30; 48(11):3712-3722. PubMed ID: 33852051
    [Abstract] [Full Text] [Related]

  • 11. Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
    Mena E, Rowe SP, Shih JH, Lindenberg L, Turkbey B, Fourquet A, Lin FI, Adler S, Eclarinal P, McKinney YL, Citrin DE, Dahut W, Wood BJ, Chang R, Levy E, Merino M, Gorin MA, Pomper MG, Pinto PA, Eary JF, Choyke PL, Pienta KJ.
    J Nucl Med; 2022 Aug 30; 63(8):1184-1190. PubMed ID: 34916246
    [Abstract] [Full Text] [Related]

  • 12. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 30; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 13. PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer.
    Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, Schomäcker K, Heidenreich A, Zlatopolskiy BD, Neumaier B, Drzezga A, Dietlein M.
    J Nucl Med; 2017 Jun 30; 58(6):947-952. PubMed ID: 27908968
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pathological predictors of 18 F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.
    Perry E, Talwar A, Taubman K, Ng M, Wong LM, Sutherland TR.
    BJU Int; 2022 Jun 30; 130 Suppl 1(Suppl 1):28-36. PubMed ID: 35768883
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
    Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G.
    Int J Radiat Oncol Biol Phys; 2020 Mar 01; 106(3):546-555. PubMed ID: 31730876
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.